Molecular mechanisms by which the mutant ASXL1/BAP1 complex aggravates myeloid leukemia

DOI Web Site PubMed
  • ASADA Shuhei
    The Institute of Laboratory Animals, Tokyo Women's Medical University Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo

Bibliographic Information

Other Title
  • 変異型ASXL1/BAP1複合体が骨髄性白血病を促進する分子メカニズム
  • 第80回日本血液学会学術集会 学会奨励賞受賞論文 変異型ASXL1/BAP1複合体が骨髄性白血病を促進する分子メカニズム
  • ダイ80カイ ニホン ケツエキ ガッカイ ガクジュツ シュウカイ ガッカイ ショウレイショウ ジュショウ ロンブン ヘンイガタ ASXL1/BAP1 フクゴウタイ ガ コツズイセイ ハッケツビョウ オ ソクシン スル ブンシ メカニズム

Search this article

Abstract

<p>Mutations in ASXL1, which occur frequently in myeloid neoplasms, often confer poor prognosis. Despite their clinical importance, the precise molecular mechanisms underlying the contribution of mutant ASXL1 to cancer pathogenesis remain to be elucidated. Thus, we analyzed the roles of the hyperactive complex formed by mutant ASXL1 and the deubiquitinase BAP1 in promoting myeloid leukemogenesis. BAP1 expression resulted in the stabilization and increased monoubiquitination of mutant but not wildtype ASXL1. Monoubiquitination of mutant ASXL1 enhanced the catalytic function of BAP1, resulting in a profound reduction in H2AK119ub by counteracting the PRC1 complex. The mutant ASXL1-BAP1 hyperactive complex impaired the multi-lineage differentiation of hematopoietic progenitor cells and accelerated myeloid leukemogenesis. Mechanistically, the mutant ASXL1/BAP1 complex induced the upregulation of HOXA5, HOXA7, HOXA9, and IRF8 via a reduction in H2AK119ub. Importantly, BAP1 depletion inhibited the leukemogenicity of mutant ASXL1-expressing myeloid leukemia cells and MLL-rearranged leukemia cells by reducing the expression levels of HOXA5, HOXA7, and HOXA9. Our findings highlight the potential of BAP1 as a therapeutic target in a broad range of myeloid neoplasms.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 61 (4), 392-405, 2020

    The Japanese Society of Hematology

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top